Zacks: Brokerages Expect Renalytix Plc (NASDAQ:RNLX) to Post -$0.17 Earnings Per Share

Analysts expect Renalytix Plc (NASDAQ:RNLXGet Rating) to post earnings per share (EPS) of ($0.17) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Renalytix’s earnings. The lowest EPS estimate is ($0.18) and the highest is ($0.17). Renalytix posted earnings of ($0.12) per share during the same quarter last year, which suggests a negative year over year growth rate of 41.7%. The business is expected to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Renalytix will report full year earnings of ($0.68) per share for the current financial year, with EPS estimates ranging from ($0.71) to ($0.64). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.54) per share, with EPS estimates ranging from ($0.66) to ($0.38). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Renalytix.

A number of research analysts have recently issued reports on RNLX shares. BTIG Research cut their price objective on shares of Renalytix from $24.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, April 1st. Zacks Investment Research lowered shares of Renalytix from a “hold” rating to a “sell” rating in a report on Wednesday, April 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Renalytix in a research report on Friday, April 1st. Finally, JPMorgan Chase & Co. reduced their target price on shares of Renalytix from $25.00 to $8.00 in a report on Friday, April 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Renalytix currently has a consensus rating of “Buy” and a consensus price target of $23.80.

Renalytix stock opened at $4.91 on Tuesday. Renalytix has a 12-month low of $4.81 and a 12-month high of $35.71. The business has a 50-day moving average price of $6.72. The company has a market cap of $183.54 million, a price-to-earnings ratio of -8.93 and a beta of 1.61.

A number of institutional investors and hedge funds have recently modified their holdings of RNLX. Skye Global Management LP bought a new stake in Renalytix during the fourth quarter worth approximately $105,000. Advisor Group Holdings Inc. lifted its position in shares of Renalytix by 201.6% in the third quarter. Advisor Group Holdings Inc. now owns 5,532 shares of the company’s stock worth $111,000 after purchasing an additional 3,698 shares in the last quarter. Morgan Stanley raised its position in Renalytix by 278.7% during the second quarter. Morgan Stanley now owns 7,093 shares of the company’s stock valued at $219,000 after acquiring an additional 5,220 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in Renalytix during the fourth quarter valued at approximately $224,000. Finally, Millennium Management LLC bought a new position in Renalytix during the fourth quarter valued at approximately $287,000. Hedge funds and other institutional investors own 16.13% of the company’s stock.

About Renalytix (Get Rating)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score.

Featured Articles

Get a free copy of the Zacks research report on Renalytix (RNLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.